A Unique & Global Healthcare Testing Company

FY2008 1Q Business Results

August 4, 2008

2

Increases both in sales and income:Achieved record-high business performanceAchieved higher sales in 5 regions including Japan

Sales composition: Japan 26%, Overseas 74%Revenue grew overseas despite a strong yen against the US dollar

1st Quarter Financial Highlights

26.1

19.7

23.6

20.8

16.7

0.9

1.91.61.5

1.72.01.9 2.0

1.7

2.52.7

1.2

0.7

1.3 1.4

0

5

10

15

20

25

30

2005.3 2006.3 2007.3 2008.3 2009.3Sales

0

1

2

3

4

5

6

Income

Sales Operating IncomeOrdinary Income Income

1Q1Q 1Q1Q1Q

(in billions of JPY)

Exchange rate in the preceding 1Q report:1US$=¥120.8, 1EUR=¥162.7

Exchange rate in this 1Q report：1US$=¥104.6, 1EUR=¥163.4

109.8%2.52.7OrdinaryIncome

104.6%1.31.4Income

118.3%1.72.0OperatingIncome

110.6%23.626.1Sales

As percentage of the 2008.3 1Q

2008.31Q

2009.31Q

(in billions of JPY)

3

Acquisition of approval from the MHLW for manufacture and sale of our in vitro diagnostic agent used for detection of breast cancer lymph node metastasisAcquisition of permission by the Ministry of Agriculture, Forestry and Fisheries for production and sale as the test kit for rapid examination of birds to check for influenza

Commencement of business contracted out from Sysmex bioMérieux in Japan

Commencement of direct sales and support and service in FranceEstablishment of a subsidiary in the Middle East

Adoption of our hematology analyzers as standard instruments by the Mongolian Ministry of Health

Japan's first

Topics

New products

Alliances

Affiliates and offices

Other

Gene amplification reagentLYNOAMP BC

Gene amplification detectorRD-100i

Sysmex France

Japan's first

4

Japan

7.37.36.5

6.6

7.8

6.2

0.91.0

0.7

0

4

8

12

16

2007.3 2008.3 2009.30.0

0.4

0.8

1.2

1.6

Sales to customers Intra-area TransferOperating Income

【Sales to customers】

Sales growth in Japan as the hematology sales grew

and hemostasis business recovered

Commencement of business contracted out from

Sysmex bioMérieux

* Including ¥440 million sales to Korea, Taiwan and Mongolia

【Intra-area Transfer】

Increase in exports to overseas affiliates

Negative impact from adverse forex situation

(strong yen / weak dollar)

13.6 13.2

15.2

1Q 1Q 1Q

* Japan segment includes sales / income in South Korea, Taiwan, Mongolia and internal group affiliates

Geographic Segment Information (Japan)

(in billions of JPY)(Sales) (Operating Income)

5

【Americas】High growth sustained in NA thanks to reinforcement ofthe direct-sale system in the hematology business

Full launch of direct sales and support in Canada

Expansion of Latin American sales due mainly to successful bids on large contracts in Brazil and Mexico

Introduction of the animal blood cell analyzers to IDEXX’slaboratories

【Europe】

Sales driven by the introduction of direct-sales in France and growth in emerging countries

Improvement of income margins as reagent sales grew

Slowdown of sales growth due to the change in accounting standards for leases

Geographic Segment Information (Americas & Europe)米州

5.9

4.04.8

△ 0.70

0.17 0.21

-3.0

-1.5

0.0

1.5

3.0

4.5

6.0

2007.3 2008.3 2009.3

△1.0

△0.5

0.0

0.5

1.0

1.5

（売上高） （営業利益）

(in billions of JPY)

<US, Canada, and Central and South America>

1Q 1Q 1Q

(Sales)Americas (Operating

Income)

欧州

9.4

7.2

9.8

0.78

1.41.0

0

2

4

6

8

10

2007.3 2008.3 2009.30.0

0.5

1.0

1.5

2.0

2.5（売上高） （営業利益）

1Q 1Q 1Q

(Sales) Europe (OperatingIncome)

6

【China 】

Brisk performance of the solution business in the high-end market

HST series, Hematology analyzer (high end)Increase in instrument sales thanks to expansion in the urinalysis businessImprovement of income margin thanks to reagent sales growthDecline in the successful bid ratio of the hematology analyzers due to regulations which favor local manufacturers

【ＡＰ】

Major growth in instrument sales in the hematology business

Successful bid on a large contract in AustraliaDelivery of systems products in Malaysia and Singapore (through direct-sales)

Expansion of production items at the Baddi reagent factory

Geographic Segment Information (China & AP)中国

1.7

1.2

1.8

0.100.14

0.19

0.0

0.5

1.0

1.5

2.0

2007.3 2008.3 2009.30.0

0.1

0.2

0.3

0.4（売上高） （営業利益

(in billions of JPY)

1Q 1Q 1Q

(Sales) China (OperatingIncome)

ＡＰ

1.00.8

1.2

0.20

0.090.13

0.0

0.3

0.6

0.9

1.2

2007.3 2008.3 2009.30.0

0.1

0.2

0.3

0.4（売上高） （営業利益）

1Q 1Q 1Q

(Sales)AP

(OperatingIncome)<Excluding Korea, Taiwan

and Mongolia>

7

Consolidated Earnings Forecast

118.0

76.9

101.0110.7

87.8 16.015.0

9.1

12.710.7

15.814.5

13.511.9

9.8

9.1 9.6

5.77.4

9.0

0

20

40

60

80

100

120

140

2005.3 2006.3 2007.3 2008.3 2009.3

Sale

s

0

5

10

15

20

25

Income

Sales Operating Income Ordinary Income Net Income

Investment planInvestment plan

FY2008 Consolidated Earnings Forecast

(Planned exchange rate : US$1= ¥100, EUR1= ¥157)

Sales : ¥118 billion Ordinary Income : ¥15.8 billion Ordinary Income ratio : 13.4%

Net Income : ¥ 9.6 billionNet Income ratio : 8.1%

Equipment: ¥12.0 billion R&D: ¥11.0 billion

(in billions of JPY)

+6.6%

+5.1%

+6.4%

+8.6%

* Revised on August 2008

8

Projected Dividend

¥ 48

¥¥ 48 48

Total

26.8%

25.6%25.6%

Dividend ratio (Consolidated)

¥ 28¥ 20FY2007FY2007

¥¥ 2424¥¥ 2424FY2008FY2008(Projected)(Projected)

Year-end dividend

Interim dividend

(Announced in May 2008)

A Unique & Global Healthcare Testing CompanyEND

<Contact>IR & Corporate Communication Div.Phone: 81-078-265-0500Email: info@sysmex.co.jpURL: www.sysmex.co.jp

Challenging the Frontiers of Healthcare Testing

SYSMEX CORPORATION

PAC_E_0803_３Ｑ_01

Forward-looking StatementsThis material contains forward-looking statements about Sysmex Corporation and its group companies (the Sysmex Group). These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it, and involve both known and unknown risks, uncertainties and other factors, including but not limited to: global economic conditions, competitive situations, and changes in exchange rates. Such risks, uncertainties, and other factors may cause the actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements, or financial position expressed or implied within these forward-looking statements.